Merck and the Merck Manuals

Delivery should be as much as possible without trauma. Manual removal of the placenta should avoid avoiding fetal cells to circulate in the mother's body.

Maternal sensitization and antibody production due to incompatibility of Rh can be prevented by administering female Rh 0 (D) immunoglobulin. The formulation contains a high titer anti-Rh antibody that neutralizes Rh positive fetal RBC. Since mothers are most at risk of metastasis and sensitization of mothers at the end of pregnancy, the formulations are administered within 72 hours of the end of each pregnancy either by pregnancy, abortion or treatment of ectopic pregnancy. The standard dose is 300 mcg IM. The rosette test can be used to rule out significant fetal bleeding and if the result is positive, the Kleihauer-Betke (acid elution) test measures the amount of fetal blood in the maternal circulation. If the test results show a large amount of fetal bleeding (> 30 mL whole blood), additional injection is required (300 mcg per 30 mL fetal whole blood, up to 5 times within 24 hours).

Since sensitization may occur during pregnancy, treatment may sometimes be ineffective if given only after childbirth or termination of pregnancy. Therefore, at approximately 28 weeks, all Rg (D) immunoglobulins of Rh-negative blood were administered to all pregnant women who had not previously been sensitized. If childbirth does not occur within 40 weeks, some experts recommend taking the second dose. Rh 0 (D) immunoglobulin should also be administered after vaginal bleeding and amniocentesis or chorionic villus sampling.

MDMA was originally synthesized by Merck chemist Anton Köllisch in 1912. At that time, Merck was interested in the development of substances that can prevent abnormal bleeding. Merck wants to avoid Hydrastinin which is a compound of existing patent held by Bayer. Köllis has developed a salicylic acid analog methylsalicylate formulation at the request of laboratory members Walther Beckh and Otto Wolfes. MDMA (referred to as Methyl Sulfonamide, Saflyl Methylamine or N-Methyl-α-Methyl High Peroxacin in Merck's Laboratory Report) is an intermediate compound in the synthesis of methylsalicylic acid. Merck was not interested in MDMA itself. On December 24, 1912, Merck submitted two patent applications describing the synthesis of MDMA and some of its chemical properties, followed by conversion to methyl salicylate.

Merck is a leading technology company that announced the establishment of the Merck Foundation today. Through this foundation, Merck has concentrated much of its corporate responsibility activities under one roof and has significantly expanded its scope to address the health, social and economic challenges of the 21st century. Frank Stangenberg-Haverkamp, ​​Chairman of the New Foundation Board, says: "The vision of the new foundation is that everyone can live in a healthy and fulfilling world, that is, in poverty." We have improved innovative healthcare solutions for disadvantaged communities, We will continue to strive to build healthcare and research capabilities and improve people's lives through science and technology. "